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A multifunctional human monoclonal neutralizing
antibody that targets a unique conserved epitope
on influenza HA
Sandhya Bangaru1, Heng Zhang2,3, Iuliia M. Gilchuk4, Thomas G. Voss4,5, Ryan P. Irving4, Pavlo Gilchuk4,
Pranathi Matta4, Xueyong Zhu2, Shanshan Lang2, Travis Nieusma2, Juergen A. Richt6, Randy A. Albrecht7,
Hillary A. Vanderven8, Robin Bombardi4, Stephen J. Kent8, Andrew B. Ward2,
Ian A. Wilson 2,9 & James E. Crowe Jr. 1,4,5
The high rate of antigenic drift in seasonal influenza viruses necessitates frequent changes in
vaccine composition. Recent seasonal H3 vaccines do not protect against swine-origin H3N2
variant (H3N2v) strains that recently have caused severe human infections. Here, we report a
human VH1-69 gene-encoded monoclonal antibody (mAb) designated H3v-47 that exhibits
potent cross-reactive neutralization activity against human and swine H3N2 viruses that
circulated since 1989. The crystal structure and electron microscopy reconstruction of H3v-
47 Fab with the H3N2v hemagglutinin (HA) identify a unique epitope spanning the vestigial
esterase and receptor-binding subdomains that is distinct from that of any known neutralizing
antibody for influenza A H3 viruses. MAb H3v-47 functions largely by blocking viral egress
from infected cells. Interestingly, H3v-47 also engages Fcγ receptor and mediates antibody
dependent cellular cytotoxicity (ADCC). This newly identified conserved epitope can be used
in design of novel immunogens for development of broadly protective H3 vaccines.
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Influenza A H1 and H3 viruses are the two major viral influ-enza A subtypes that currently circulate in humans throughoutthe world. Since H3N2 viruses began circulating in the human
population in 1968, they have caused higher morbidity and
mortality rates during their dominant seasons than H1N1 or
influenza B viruses, and therefore present a substantial health
challenge1–3. Due to the high rate of antigenic drift and rapid
evolution of human H3 viruses4,5, H3 vaccine strains need to be
changed frequently to remain effective6,7. During the global
2014–2015 influenza season, H3N2 viruses predominated,
accounting for more than 90% of all subtyped influenza A
viruses8,9. In addition to seasonal infections, influenza A H3N2
variant (H3N2v) viruses of swine-origin have caused sporadic
influenza infection in humans following direct exposure to
swine10. These variant strains are triple reassortant viruses, with
their genes originating from swine, avian, and human viruses,
including the matrix (M) gene from the 2009 pandemic H1N1
virus10. In recent years, there has been a significant increase in the
number of cases of H3N2v human infection, with more than 350
confirmed infections in the US since 201110,11. H3N2v viruses
have the capacity for efficient replication and transmission in
ferrets12, and may pose a pandemic threat similar to that of the
swine-origin 2009 pandemic H1N1 virus. More importantly, the
H3N2v influenza viruses are antigenically distinct from seasonal
influenza viruses13, and current vaccines are not effective in
protecting against these variant strains14–17.
Influenza A viruses have two major surface glycoproteins,
hemagglutinin (HA) and neuraminidase (NA). The trimeric HA
protein is critical for facilitating virus entry and infection of host
cells and is the major target of neutralizing antibodies18,19. The
HA can be divided functionally into three major regions: (1) the
receptor-binding subdomain (RBS), (2) the vestigial esterase
subdomain located lower down on the HA globular head, and (3)
the membrane-proximal stem region that is responsible for the
low pH-triggered membrane fusion activity of HA in endosomal
compartments20,21. Antigenic drift of the HA can act as a driving
force for viruses to escape the human immune response4,22. HA
antibodies can be grouped generally into those that recognize the
head or stem domains. To inhibit viral infection, HA head-
binding neutralizing antibodies usually block viral attachment,
while HA-stem binding antibodies can prevent fusion between
the viral and endosomal membranes and proteolytic activation of
the HA0 precursor protein to HA1/HA223. The classic antigenic
sites on the immunodominant head domain of HA can be clus-
tered generally in five sites in H3 HA designated A, B, C, D, or
E24,25 or five sites in H1 HA designated Sa, Sb, Ca1, Ca2, or Cb26.
Sites A and B (or Sa and Sb) are proximal to the receptor-binding
site, sites C and D (Ca1 and Ca2) are at the subunit interface, and
site E (Cb) is within the vestigial esterase domain. More recently,
a broad influenza B antibody CR8071 that binds the vestigial
esterase domain on HA head was shown to function primarily by
inhibiting viral egress, similar to the function exhibited by NA
inhibitors23,27. Another study demonstrated that HA antibodies
possess some level of egress inhibition activity, possibly mediated
by Fc-mediated steric hindrance of NA active site28.
In addition to the neutralization mechanisms mentioned
above, antibodies to influenza proteins are capable of mediating
additional effector functions through their Fc region using anti-
body dependent cellular cytotoxicity (ADCC)29,30 or antibody-
dependent phagocytosis (ADP)31. ADCC is mediated when the
Fc region of the antibodies that are bound to viral antigen on
infected cells interact with FcγRIIIa (CD16a) on the surface of
NK cells, resulting in crosslinking of FcγRIIIa. Subsequent NK
cell activation triggers killing of virus-infected cells by releasing
perforins and granzymes along with secretion of antiviral cyto-
kines. In recent years, ADCC elicited by influenza antibodies has
emerged as a factor that may contribute to the protective
immunity afforded by stem antibodies in vivo32. However, neu-
tralizing antibodies to the head domain that block receptor-
binding sites typically are not thought to possess ADCC
activity32,33.
Due to the significant health threat posed by H3N2 strains, it
would be beneficial to develop a vaccine that targets a conserved
epitope on HA and induces breadth of response against both
human and swine H3 strains. Broadly neutralizing antibodies to
influenza virus, often encoded by the human VH1-69 germline
gene segment27,34,35, generally target the structurally conserved
HA stem domain27,34–38.
Here, we report that a human VH1-69 gene-encoded mAb
designated H3v-47, selected after immunization with a subunit
experimental vaccine candidate based on the novel reassortant
swine-origin vaccine strain (A/Minnesota/11/2010), possesses
broadly neutralizing activity against both human and swine
H3N2 viruses. In vivo studies with mice that were treated pro-
phylactically or therapeutically with H3v-47 showed protection
against weight loss and death following lethal virus challenge.
Structural studies revealed that H3v-47 recognizes a unique epi-
tope spanning the RBS and vestigial esterase region that is con-
served in recent H3 viruses. Interestingly, H3v-47 functions
primarily by inhibiting viral egress and also effectively engages Fc
receptor to elicit ADCC activity. These findings identify a novel
conserved epitope on H3 HA that can aid in development of a
broad H3N2 vaccine and provide insights into unique antiviral
approaches exploited by a vestigial esterase domain-binding
antibody.
Results
Broad activity against human and swine H3N2 strains. We
previously reported the isolation of H3v-reactive human mono-
clonal antibodies (mAbs) from donors vaccinated with an
experimental H3N2v vaccine containing the A/Minnesota/11/
2010 strain39,40. To investigate the breadth of one of these mAbs
(H3v-47) further, we tested for binding by ELISA against a panel
of recombinant HA molecules expressed from the HA genes of
seasonal H3N2 strains that circulated during 1968–2014. MAb
H3v-47 showed strong binding to H3N2 strains that circulated
after 1989 (EC50 from 19 to 169 ng/mL) (Table 1). We also
compared relative binding of H3v-47 Fab or IgG to a panel of
seasonal H3 HAs by bio-layer interferometry. Consistent with the
ELISA data, H3v-47 IgG exhibited high affinity to HA from
seasonal H3 strains that occurred between 1989 and 2011 (Kd < 1
pM) whereas H3v-47 Fab displayed moderate-high affinity of
binding to HA from H3 strains that circulated after 1989 (Kd
from 224 nM to <1 pM) (Supplementary Table 1 and Supple-
mentary Figure 1). Thus, H3v-47 can recognize HA molecules
representing the diversity present in a 25-year time period from
1989 to 2014, during which significant antigenic drift occurred in
human seasonal H3N2 viruses. Although binding was not
detected for H3v-47 Fab to the HA of influenza strains isolated
before 1989, its IgG demonstrated moderate avidity (Kd from 69
to 130 nM) for binding to these strains (Supplementary Table 1
and Supplementary Figure 1). H3v-47 did not show any binding
to HA proteins from the four other influenza A subtypes tested
(H1, H2, H5, or H7) (Supplementary Table 1).
The in vitro neutralization activity for this mAb was largely
consistent with the binding data. H3v-47 showed strong
neutralization against all tested H3 strains isolated after 1989
but had considerably lower neutralizing activity against
H3 strains isolated before 1989 (Table 1). We also compared
relative neutralizing activity exhibited by H3v-47 Fab, F(ab′)2, or
IgG against H3N2v A/Minnesota/11/2010 virus. While the
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F(ab′)2 form of H3v-47 neutralized at a similar potency to the
IgG, H3v-47 Fab displayed a greater than 190-fold reduction in
the IC50 value in comparison to IgG (<1 pM) (Supplementary
Figure 2). Thus, H3v-47 requires the bivalency of IgG to potently
neutralize the virus.
Since most healthy adult donors were partially immune to
H3 seasonal viruses prior to experimental vaccination with the
H3N2v-based subunit vaccine candidate, we cannot be sure that
this antibody arose as a component of the primary response to
the H3N2v antigen from a naive B cell. However, when tested for
neutralization against swine viruses representing each antigenic
cluster circulating in swine, A/Swine/Texas/4199-2/98 (cluster I),
A/Swine/Colorado/23619/99 (cluster II), A/Swine/Oklahoma/
18089/99 (cluster III), or A/Ohio/13/2012 (cluster IV), it was of
interest that H3v-47 efficiently neutralized all four swine
H3N2 strains (Table 1), which has not been reported previously
for human H3 antibodies34,36,38,41. These data suggest that H3v-
47 possesses broad-spectrum neutralizing activity for viruses of
the H3 subtype and can efficiently inhibit both human and swine
H3N2 viruses.
Lethal H3N2v A/Minnesota/11/2010 mouse challenge model.
We next sought to determine if mAb H3v-47 could prevent or
treat infection with the H3N2v A/Minnesota/11/2010 virus.
There is no established robust small animal infection model for
this virus, so first we developed a lethal respiratory challenge
model. Two groups of DBA/2 J mice (n= 15 per group) were
inoculated i.n. with ∼1.2 × 105 (high dose), or ∼1.2 × 104 (low
dose) FFU of A/Minnesota/11/2010 ×−203 virus stock and
monitored for 7 days for weight change kinetics. The results
showed a dose-dependent response to the virus, and the highest
dose caused mortality (Supplementary Figure 3a and 3b; note this
figure shows body weight only for the animals that survived based
on actual death between watches or endpoint for euthanasia). We
also measured lung virus titers on dpi 1, 3, 5, 7, or 12 lungs (n= 3
per time point for each group), which showed the peak lung titers
occurred on dpi 5, and mortality occurred during dpi 4–7
(Supplementary Figure 3c and 3d). We chose to use an inter-
mediate dose in the prophylactic and therapeutic studies (6 × 104
FFU) that was expected uniformly to cause ≥20% weight loss, a
point beyond the mice could not recover, and to collect lungs for
virus titer on dpi 4.
Prophylactic and therapeutic administration of H3v-47 in
mice. Groups of mice were inoculated i.p. with 10 (high dose) or
1 mg/kg (low dose) of mAb H3v-47 on the day before (day −1,
prophylaxis), or on day one (day +1, treatment) after lethal
respiratory (i.n. route) challenge and monitored for 10 days. The
control groups included mice treated with PBS (mock control) or
the previously described mAb CR8020. In the prophylaxis setting,
the high dose of mAb H3v-47 completely protected against
weight loss (Fig. 1a) and clinical disease (Fig. 1c). The low dose
prophylaxis reduced weight loss and completely protected against
clinical disease (Fig. 1a). In the treatment setting, the high and
low dose of mAb H3v-47 protected against severe weight loss and
a fatal endpoint (Fig. 1b), and both regimens had a moderate
clinical score benefit comparable to that of CR8020 (Fig. 1d).
MAb H3v-47 mediated a moderate but significant effect on virus
titers in lungs on 4 dpi after prophylaxis after high or low dose
administration (Fig. 1e), but neither mAb H3v-47 nor CR8020
had a significant effect on lung virus in the therapeutic setting
(Fig. 1f). In summary, H3v-47-mediated protective clinical ben-
efits in both prophylactic and therapeutic settings.
Epitope map and structure of the H3v-47-HA complex. In our
original report on isolation of H3v-reactive antibodies, it was
apparent that H3v-47 does not bind to the RBS on HA head in a
conventional manner due to its lack of hemagglutination
Table 1 H3v-47 IgG breadth of HA binding and virus neutralization for human or swine H3N2 viruses
Virus Strain Binding EC50 (ng/mL) Neutralization IC50 (ng/mL)
H3N2v A/Minnesota/11/2010 4 8
Human H3N2 strains A/Hong Kong/1/1968 > >
A/Victoria/3/1975* > >
A/Bangkok/1/1979* NT >
A/Leningrad/360/1986* NT >
A/Beijing/353/1989* NT 158
A/Shandong/9/1993* NT 223
A/Wuhan/359/1995* NT 127
A/Sydney/5/1997* 24 385
A/Panama/2007/1999* 20 2217
A/Fujian/411/2002* 27 578
A/New York/55/2004* 22 210
A/California/7/2004* 35 NT
A/Hiroshima/52/2005* 25 NT
A/Wisconsin/67/2005* NT 2741
A/Brisbane/10/2007* NT 1632
A/Perth/16/2009* 19 711
A/Victoria/361/2011* 19 1170
A/Texas/50/2012* 31 598
A/Switzerland/9715293/2013* 169 718
A/Hong Kong/4801/2014* NT 167
Swine H3N2 strains (Cluster I–IV) A/Swine/Texas/4199-2/98 NT 1220
A/Swine/Colorado/23619/99 NT 200
A/Swine/Oklahoma/18089/99 NT 340
A/Ohio/13/2012 NT 670
NT not tested. *WHO H3N2 vaccine strain for indicated year. '>' symbol indicates values >10,000
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04704-9 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2669 | DOI: 10.1038/s41467-018-04704-9 | www.nature.com/naturecommunications 3
inhibition (HAI) activity39. To examine if the antibody binds to
the stem region, we used bio-layer interferometry to compete
H3v-47 for binding against other known broad stem-binding
antibodies including CR8020, CR9114, FI6v3, and 39.29 as well as
the control RBS-binding antibody, C05. Surprisingly, we observed
partial competition between H3v-47 and the RBS mAb C05, but
did not detect competition with the stem-binding antibodies,
indicating that H3v-47 does not bind to the HA stem region
(Fig. 2).
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Fig. 1 Prophylactic and therapeutic efficacy of mAb H3v-47 in mice. Groups of DBA/2J mice were inoculated i.p. with 10 (high dose) or 1 mg/kg (low dose)
of mAb H3v-47 on the day before (day −1, prophylaxis), or on day one (day +1, treatment) after lethal respiratory (i.n. route) challenge with ∼ 6 × 104
focus forming units (FFU) of A/Minnesota/11/2010 ×−203 virus and monitored for 10 days. The control groups included mice treated with PBS (mock
control) or the previously described mAb CR8020. The protective efficacy of mAbs was assessed by weight change kinetics (a, b), clinical score (c, d), and
virus titers in lungs on 4 dpi (e, f). The dotted line (a, b) indicates the IACUC stipulated endpoint for humane euthanasia. Data in a, b shows body weight
only for the animals that survived based on actual death between watches or endpoint for euthanasia, and represents the mean value ± SEM, using 10 mice
per group. Each group was compared to the PBS-treated group using two-way ANOVA with Dunnett‘s post-hoc test for a, b, and one-way ANOVA with
Dunnett‘s post-hoc test for e, f. Dots in e, f indicate individual mice (n= 5 mice per group). The median titer is shown with the line, and the dotted line
indicates the limit of detection (LOD). *p < 0.05; **p < 0.01; ***p < 0.001 were considered significant
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To further investigate the antibody epitope, we determined the
crystal structure of H3v-47 Fab in complex with H3N2 A/
Minnesota/11/2010 (Minn2010/H3v) HA, at 3.57 Å resolution
(Supplementary Table 2). Initial phases were obtained by
molecular replacement using high-resolution structures that we
also determined for H3v-47 Fab at 2.57 Å resolution and
Minn2010/H3v HA-LSTc at 2.90 Å resolution (instead of the
apo HA form at 3.15 Å, see below) (Supplementary Table 2).
Despite the moderate resolution, the main chain and most side
chains for the Fab and HA had interpretable electron density
(Supplementary Figure 4). One HA protomer with one Fab was
present in the asymmetric unit. The Fab binds to the globular
head of HA below the RBS, in a region near the vestigial esterase
subdomain (Fig. 3a, b and Supplementary Figure 4). Negative-
stain EM reconstructions of the complex at 25.8 Å also showed
that H3v-47 binds the HA head domain (Supplementary
Figure 5). The position of the binding region suggested that
H3v-47 cannot block the sialic acid-binding pocket, which is
consistent with the observation that H3v-47 does not exhibit HAI
activity. A total area of 1061 Å2 is buried at the antibody-antigen
interface (511 Å2 on HA and 550 Å2 on the Fab), where the heavy
and light chains contribute to 61% and 39% of the Fab buried
surface area, respectively. Major conformational changes were not
observed in the Minn2010/H3v HA upon complex formation
when compared to the apo form of the HA, except for differences
in a few side-chain rotamers.
H3v-47 targets a unique conformational epitope spanning the
RBS and vestigial esterase region in the HA head mainly using the
complementarity determining regions (CDRs) H2 and H3 from
the heavy chain and L1 and L3 from the light chain (Fig. 3b). A
total of 23 residues from Minn2010/H3v HA participate in
intermolecular contacts (Fig. 3c), making a total of 18 hydrogen
bonds (H bonds)/salt bridges with both heavy and light chains, as
well as 96 van der Waals (VDW) interactions (Fig. 3d, e). PheH54
from CDR H2 (a signature residue on CDR H2 of VH1-
69–encoded germline antibodies), and ProH100a, ProH100d, and
TyrH100f from CDR H3, mediate the hydrophobic interactions
with the HA. Footprint residues 77–83 in the vestigial esterase
subdomain are classified as being part of the H3N2 antigenic site
E, while residues 119–124, 133, 141–149 in the RBS are within
antigenic site A (Fig. 3c). These two regions are bound by H3v-47
mainly through its heavy chain (CDRs H2 and H3) and light
chain (CDRs L1, and L3), respectively, accounting for ~90% of
the total contacts. For example, Lys82 in the antigenic site E
makes one salt bridge by its side chain (Nζ) with AspH64 (Oε2),
and eight VDW interactions with Gln61H and AspH64, mainly
from its main chain (Fig. 3e). Moreover, the key residue Asp133
in the receptor binding pocket can make VDW contacts with
GluH100 (Fig. 3e). In addition, ArgL69 side chain (Nη2) in
framework region 3 (FR3) makes one salt bridge and one VDW
contact with the side chain and main chain of Asp172 on the edge
of the epitope, which may further stabilize the binding interface
between the HA and Fab.
Sequence analysis of natural variation in the H3v-47 epitope.
The distinct neutralization profile of H3v-47 against
H3N2 strains isolated before or after ~1989 indicates that natu-
rally occurring variation in the epitope has a considerable effect
on H3v-47 binding. The H3v-47 epitope is quite variable across
human H3 virus strains in the National Center for Biotechnology
Information (NCBI) Influenza database, with only 10 out of 23
contacting residues (77, 80, 119, 120, 141, 147, 149, 255, 257, and
259) being highly conserved (99–100%), and the remaining
residues moderately conserved (7–82%) (Supplementary Table 3).
The H3v-47 epitope is markedly less conserved than HA stem
epitopes recognized by broadly neutralizing stem-specific anti-
bodies, such as CR6261 and CR802033,34. However, H3v-47 can
tolerate natural variation in H3 vaccine strains spanning from
1989 to 2015. Variability within the footprint of H3 HAs may
account for the large difference in H3v-47 binding affinities to
H3 strains isolated before or after 1989. We performed a
sequence alignment of 12 H3N2 HAs covering the 1968 pan-
demic to 2012 strains (Supplementary Table 4) that were
used for binding assays (Supplementary Table 1). A lysine at
position 82 in antigenic site E emerged in 1989 among the
eight representative H3N2 strains that can be efficiently neu-
tralized by H3v-47, whereas glutamic acid was present in
H3N2 strains isolated before 1989. At position 124 in
antigenic site A, serine and glycine are prevalent before and after
1989, respectively, except for aspartic acid in the Beijing 1989
and Shandong 1993 strains that have moderate Fab binding to
H3v-47, but strong IgG avidity.
H3v-47 C05 CR8020 CR9114 FI6v3 39–29
H3v-47 4 49 100 94 108 78
C05 46 0 94 114 91 91
CR8020 94 99 0 0 0 0
CR9114 71 89 3 5 21 24
FI6v3 94 98 11 42 0 37
39-29 55 86 2 27 24 0
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Fig. 2 Competition binding of H3v-47 with other influenza head- or stem-
binding antibodies. Competition-binding assays were performed using
biolayer interferometry. The His-tagged A/Minnesota/11/2010 H3N2v HA
was loaded onto Ni-NTA tips, and binding of two successively applied
antibodies (IgG) was tested. MAb H3v-47 was competed against mAb
C05, a receptor binding site mAb or each of four stem-binding antibodies:
CR8020, CR9114, 39.29, or FI6v3. Numbers indicate normalized percent
level of association to HA, compared to uncompeted control (100%). The
colored boxes indicate each competition-binding group. There was partial
overlap between group 1 and 2, shown in cyan and blue, respectively.
Competition was not detected between H3v-47 and the stem antibodies
indicated in the red competition-binding group box. The experiment was
conducted twice independently
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04704-9 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2669 | DOI: 10.1038/s41467-018-04704-9 | www.nature.com/naturecommunications 5
Mutagenesis studies of the H3v-47 epitope. The two natural
variants K82 and S124 in Minn2010/H3 HA were mutated to
glutamic acid and glycine, respectively, to study their interactions
with H3v-47. Binding of H3v-47 Fab was not detected
either for the single K82E or double K82E/S124G mutant, while
binding of S124G was much weaker (~50% of the wild-type
protein, due to a faster off rate; Supplementary Figure 1 and
Supplementary Figure 6a). However, both K82E and K82E/S124G
retained as strong binding to H3v-47 IgG as the wild-type, which
may suggest a bivalent mode of binding and the presence of
avidity effects that compensate for weaker Fab binding, as
observed for other antibodies to the HA head42,43. Meanwhile,
most footprint residues in H3 subtype viruses are distinct from
the residues at the same position in other virus subtypes (Sup-
plementary Table 4), revealing why H3v-47 does not show cross-
neutralization against other virus subtypes. Substitutions K82E
and S124G likely would abolish the H-bonds (mediated by their
side chains) and many VDW contacts (mainly by their main
chains) with H3v-47 in the structure (Fig. 3e). K82E also changes
the electrostatics on the HA surface, from positive Lys to negative
Glu, causing unfavorable binding to H3v-47 (Supplementary
Figs. 6c, d).
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We attempted to isolate antibody resistant (“escape”) mutant
viruses in laboratories at two different institutions. At neither site
were we able to obtain escape mutants for mAb H3v-47,
suggesting that viral escape to this antibody does not occur
readily in vitro.
N-glycosylation of H3v-47 combining site in Minn2010/H3v
HA. Increase of N-glycosylation sites in the HA head domain is
associated with shielding of the antigenic sites against antibody
recognition during their evolution44,45. The 1968 pandemic H3
HA carries only two N-glycosylation sites on the globular head
region (at positions 81 and 165), whereas seasonal human H3
HAs gradually have acquired up to six additional sites (at posi-
tions 63, 122, 126, 133, 144, and 165) during the period leading
up to 2012. In Minn2010 H3v/HA, there are only four N-
glycosylation sites in the globular head region (at positions 63,
126, 165, and 246; Supplementary Figure 7). The only two gly-
cosylation sites N63 and N126 in the HA around the near the
epitope do not make any contacts in the antibody-antigen
interface (Supplementary Figure 6e).
Importantly, three H3v-47 epitope residues on Minn2010/H3v
HA, Q122, D133, and V144, correspond to the acquired N-
glycosylation site residues N122, N133, and N144 in recent
seasonal H3 viruses (Supplementary Figures 6f and 7). Structural
superposition of the present complex with the apo-structure of
H3 HA from the seasonal A/Victoria/361/2011 (H3N2) virus
(PDB code 4O5N) shows that the glycans at N122, N133, and
N144 could make direct contacts with H3v-47, or could result in
steric hindrance [n.b. the glycans in N122 and N144 are not
modeled in this structure due to lack of electron density43,
(Supplementary Figure 6f)]. However, it was reported that the
binding of antibody FI6v3 can render an orientation change of
the N38 glycan in HA from A/Aichi/2/1968 (H3N2) (PDB code
3ZTJ) compared to the HA apo-structure34. Similar glycan
motions for formation of the complex with antibody CR9114 also
have been suggested in N38 in H3 HA and N322 in influenza B
HA23,27. Following this idea, the orientation of N-glycans
attached to these epitope residues 122, 133, and 144 also might
be variable and adaptable for H3v-47 binding in seasonal H3N2
viruses. Indeed, single mutation individually and even their
combination of Q122, D133, or V144 of Minn2010/H3v HA to
asparagine did not affect H3v-47 binding significantly as
compared to the wild-type HA (Supplementary Figures 1 and
6a). Therefore, H3v-47 can overcome antigenic site masking by
glycosylation at residues 122, 133, or 144, and therefore has broad
cross-protective potential for seasonal H3N2 strains.
Mechanism of neutralization by mAb H3v-47. Although mAb
H3v-47 binds to the HA head region, it does not neutralize by
blocking the RBS like most other head domain reactive neu-
tralizing antibodies. To further explore the mechanism of
neutralization mediated by H3v-47 recognition of this unusual
epitope, trypsin digestion of Minn2010/H3v HA was performed
in which the HA protein was exposed to a low pH (pH 5.0) to
trigger the pH-induced conformational changes and acquire
sensitivity to trypsin cleavage (Supplementary Figure 8). As
expected, the low-pH-treated HA could be completely digested by
trypsin in the absence of H3v-47 Fab. Binding of H3v-47 Fab to
the HA did not protect the HA from degradation by trypsin when
treated at pH 5.0, suggesting binding of H3v-47 does not prevent
the low-pH induced conformational changes in HA as do stem-
binding antibodies23.
We next tested whether H3v-47 functions through an
alternative mechanism by blocking virus budding. We performed
virus egress inhibition assays using MDCK cells inoculated with
Minn2010/H3v virus that were treated with H3v-47 IgG at 3 h
post inoculation to allow for unhindered virus attachment and
fusion. The neuraminidase inhibitor zanamivir or the stem-
specific neutralizing mAb CR8020 IgG were used in parallel as
positive or negative control reagents, respectively, for egress
inhibition. The assay was performed in the absence of trypsin to
restrict viral replication to a single cycle. Infected cell super-
natants were collected after 12 h, and the virus titers were
determined by hemagglutination assay as HA units. A 50%
reduction in the HA titer of virus compared to the untreated
control was observed at concentrations of 4–10 ng/mL of the
H3v-47 antibody (Fig. 4). This concentration correlates well with
the IC50 of 8 ng/mL seen for H3v-47 against the Minn2010/H3v
virus, suggesting that the main mechanism of neutralization by
H3v-47 is inhibition of viral egress. As expected, zanamivir that
blocks NA activity also showed potent inhibition of viral egress at
similar molar concentrations as H3v-47, whereas the stem-
binding antibody CR8020 did not mediate significant reduction
in HA titer at concentrations as high as 3.3 µg/mL (Fig. 4). We
did observe, however, some activity for CR8020 at the highest
concentration tested (10 µg/mL). The cause for this activity is
uncertain. This reduction in HA titer at higher antibody
concentrations could be a result of minor inhibition of NA
enzymatic activity exhibited by HA stem antibodies28.
To confirm that H3v-47 was acting at the step of virus egress
from infected cells, we performed transmission electron micro-
scopy (TEM) of MDCK cells inoculated with Minn2010/H3v
virus and either untreated or treated with H3v-47 IgG, CR8020
IgG, or zanamivir at 3 h postinoculation. As expected, the major
phenotype observed in zanamivir-treated cells was cell surface
aggregation of fully formed virus particles, in contrast to the
prevalence of released virus particles in the untreated cells (Fig. 5a
and Supplementary Figure 9). H3v-47 mAb-treated cells also
revealed virus aggregations on the cell surface, similar to those in
the zanamivir-treated samples (Fig. 5a and Supplementary
Figure 9a). In contrast, cells treated with stem mAb
CR8020 showed individually budded particles resembling the
pattern in untreated virus-infected cells (Fig. 5a and
Fig. 3 Crystal structure of antibody H3v-47 Fab in complex with H3N2v HA (A/Minnesota/11/2010) and identification of the epitope. a Overall structure
of the H3v-47 Fab- H3N2v HA complex. One HA/Fab protomer of the trimeric complex is colored with HA1 in yellow, HA2 in orange, Fab heavy chain in
green, and Fab light chain in cyan. N-linked glycans are depicted as colored balls representing their atom types (carbon in pink, oxygen in red and nitrogen
in blue). The other two protomers are in gray, but the third Fab molecule is hidden behind the HA trimer. b Zoomed-in view of the interaction between
H3N2v HA and H3v-47 Fab with color coding as in a. H3v-47 Fab binds to the region spanning the receptor-binding and vestigial esterase sub-domains
(shown as a solid surface in yellow and wheat, respectively) mainly using CDRs H2, H3, L1, and L3. The contact regions ascribed to antigenic sites A and E
are highlighted in orange or red, respectively. c H3v-47 epitope mapped onto the H3N2v HA surface. The footprint of antibody H3v-47 on the HA shows
the central role of antigenic E site residues for H3v-47 binding. The interacting surface contributed by residues from antigenic sites A or E is colored in red
or orange, respectively, whereas residues that contribute to the epitope outside of these two antigenic sites, are colored in yellow. d Antibody contact
residues (sticks) that interact with the HA with CDRs H2, H3, L1, L3, and FR3 in the light chain. e Specific interactions (H-bonds, salt bridges, hydrophobic
interactions, and VDW contacts) between H3v-47 and its footprint residues shown as sticks. The H-bonds and salt bridges are labeled using dash lines
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04704-9 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2669 | DOI: 10.1038/s41467-018-04704-9 | www.nature.com/naturecommunications 7
Supplementary Figure 9a). CR8020-treated cells also had
considerably more virus particles inside the cells compared to
zanamivir- or H3v-47-treated cells (Supplementary Figure 9a).
Zanamivir-treated cells displayed more filamentous influenza
particles on the cell surface compared to H3v-47-treated cells
(Supplementary Figure 9a). Taken together, these data indicate
that H3v-47 mAb functions by preventing viral egress in a
manner comparable to zanamivir.
Antibodies to HA have been hypothesized to inhibit viral
egress either by blocking NA enzymatic activity by Fc-mediated
steric hindrance or by cross-linking newly formed virions or HA
trimers on the cell surface23. To further elucidate the molecular
mechanism by which H3v-47 inhibits egress, we performed TEM
with gold labeling to determine the localization of H3v-47 during
egress. The infected MDCK cell samples were prepared for TEM
as before, but with the addition of anti-human IgG conjugated to
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Fig. 4 Inhibition of egress of A/Minnesota/11/2010 H3N2v virus by IgG of mAbs H3v-47 or CR8020 or by the small molecule neuraminidase inhibitor
zanamivir. Twenty-hours prior to the experiment, MDCK cells were seeded on 6-well plates in DMEM+ 5% FBS. The cells were washed twice with PBS
and inoculated with a previously optimized amount of A/Minnesota/11/2010 H3N2v virus that is required to achieve 90–100% infection. After 1 h
incubation at 37 °C, the cells were washed twice with PBS and replenished with 1.5 mL plain Opti-MEM I medium. After 3 h, the cells were washed again
and replenished with 1.5 mL of Opti-MEM I medium containing serial dilutions of the antibodies or zanamivir. The cells were incubated at 37 °C for 12 h,
and the supernatants were collected. The supernatants were diluted serially 11 times and added to an equal volume of 0.5% turkey RBCs in v-bottom plates
to determine the virus titer by hemagglutination assay. Dotted line represents virus titer in supernatant in the absence of antibody treatment. The
experiment was conducted three times independently. The hemagglutination assay to determine virus titer was also conducted three times independently
(n= 3). The significance in the reduction of HA titer between H3v-47 and CR8020 was calculated at each concentration using 2-way ANOVA and
displayed on the graph as ***(P < 0.001). Error bars indicate standard error of the mean (SEM)
mAb CR8020ZanamivirmAb H3v-47 Untreated
a
b
Fig. 5 H3v-47 localizes to interfaces between virus and cell surface or between viral particles. a TEM images of the surface of MDCK cells inoculated with
A/Minnesota/11/2010 H3N2v virus and infected cells were incubated with mAb H3v-47, zanamivir, mAb CR8020, or plain Opti-MEM at 3 h
postinoculation and fixed for imaging at 14 h. For each image, the virus particles in the red squares are shown at higher magnification, below.
Representative images of two independent experiments are shown. The white scale in each image represents 500 nm. b TEM images are shown of the
surface of MDCK cells that were inoculated with virus and subsequently incubated with H3v-47 mAb similar to a, with addition of anti-human IgG
conjugated to 10 nm gold particles at 13 h post-inoculation. The black opaque dots indicated by the red triangles represent the gold particles. The white
scale in each image represents 100 nm. The experiment was conducted twice independently
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04704-9
8 NATURE COMMUNICATIONS |  (2018) 9:2669 | DOI: 10.1038/s41467-018-04704-9 | www.nature.com/naturecommunications
gold particles 1 h before fixing cells. We observed that H3v-47
was predominantly present at the interface between the MDCK
cells and newly budded virus particles or at virus–virus interfaces
in comparison to CR8020 (Fig. 5b and Supplementary Figure 10).
The ratio of the number of gold particles present at the interfaces
(I) (virus–virus and surface–virus) to the total number of gold
particles on the surface (S) was higher for H3v-47 (I/S= 5 of 8)
compared to CR8020 (I/S= 2 of 8). Also, there was significantly
less gold particle labeling of IgG on the cell surface of CR8020-
treated cells (Supplementary Figure 10). Trace amounts of gold
particles were present in zanamivir-treated and untreated cells
(Supplementary Figure 10. Collectively, these results along with
our previous observation that the F(ab′)2 form of H3v-47 had
similar neutralization potency as the IgG (Supplementary
Figure 2), suggests that H3v-47 may primarily function by
tethering newly formed virions to the cell surface or to other viral
particles rather than Fc-mediated steric hindrance of NA.
However, it is possible that H3v-47 also possesses some level of
neuraminidase enzymatic inhibition activity that contributes to
its overall potency.
H3v-47 mAb exhibits ADCC activity. HA stem-reactive anti-
bodies frequently possess ADCC activity and depend on Fc
receptor engagement to confer protection in vivo32,46. Recent
work suggested that, while stem-binding antibodies potently elicit
ADCC activity, the receptor-binding site antibodies seem to lack
the ability to induce ADCC46,47. To examine if H3v-47, which
targets the vestigial esterase subdomain on the HA head, could
mediate ADCC activity, we first performed an ELISA using
recombinant soluble (rs), dimeric, low-affinity ectodomains
(rsFcγR) of FcγRIIIa as described48. These dimers require
simultaneous engagement of two Fc domains to achieve stable
binding detected by ELISA. We tested the ability of three mAbs
[H3v-47, H3v-12 (HA-reactive), or VRC01 (an HIV-reactive
control mAb)] bound to A/Sydney/5/1997 HA to simultaneous
engage both binding sites on rsFcγR. Only H3v-47 bound to FcγR
in this assay (Fig. 6a), suggesting its potential to mediate ADCC
activity. Next, we examined the ability of these antibodies to
mediate functional ADCC activity as measured by activation of
primary CD3− CD56+ NK cells following incubation with HA
from A/Sydney/5/1997. NK cell activation was measured by
intracellular IFN-γ expression and degranulation (CD107a
expression). A concentration-dependent increase in the percen-
tage of NK cell activation was observed for H3v-47 (14.8% NK
cell activation at 10 µg/mL), while activation was not observed for
H3v-12 or VRC01 at the highest concentration tested (10 µg/mL)
(Fig. 6b). Collectively, these data show that mAb H3v-47 engages
FcγRIIIa and induces ADCC activity, even though it binds to the
head domain.
Discussion
Recent research on influenza vaccinology has focused on the idea
of identifying components of a broadly protective or universal
vaccine that would protect better against seasonal drift virus
strains or newly emerging pandemic strains. The most obvious
conserved antigenic site for inclusion in such a vaccine studied to
date is the stem region, which possesses highly conserved residues
that can be recognized by human antibodies. Here, we describe
the unique human mAb H3v-47 that mediates very broad neu-
tralization of H3 influenza viruses by binding to an unusual
conserved epitope on the side the H3 HA head domain. This
antibody mediates inhibition of virus replication using multiple
molecular mechanisms including inhibition of virus egress and
mediation of ADCC activity. H3v-47 IgG protected animals
against weight loss and disease when administered prophylacti-
cally or therapeutically. The detailed structural and functional
data presented here suggest that engineered HA head domain
antigens that focus the antibody response on the H3v-47 epitope
could be an important component of a broadly protective H3
vaccine.
Most neutralizing antibodies that bind to the HA head of
H3N2 viruses recognize epitopes in or surrounding the RBS,
mainly using interactions mediated by the antibody heavy chain
(for instance, mAbs C05, F045-092, S139/1, HC19, and HC63)49.
The binding sites of these antibodies overlap extensively (Fig. 7a),
although they use very different angles of approach and relative
orientations of their light and heavy chains. Three structurally
characterized H3-neutralizing antibodies, HC45, BH151, and
F005-126, bind to a region more distant from the RBS, using both
light and heavy chains (Fig. 7a). The footprint of H3v-47 on HA
is unique compared with these known antibodies, although their
footprints slightly overlap (HA1 D78 in HC45, and D172 and
O
pt
ic
al
 d
en
si
ty
 a
t 4
50
 n
m
%
 N
K
 c
el
l a
ct
iv
at
io
n
(e
xp
re
ss
in
g 
C
D
10
7a
 a
nd
/o
r 
IF
N
γ)
0.6
0.4
0.2
0.0
H3 A/Sydney/5/1997H3 A/Sydney/5/1997
15
10
5
0
mAb
H3v-47
H3v-12
VRC01
Antibody concentration (μg/mL)Antibody concentration (ng/mL)
0.
1 1 10 0.
1 1 10 0.
1 1 10
mAb
H3v-47
H3v-12
VRC01
10,000 2500 625 156 39 9.8 2.4 0.6
ba
Fig. 6 H3v-47 mAb exhibits ADCC activity. a Cross-linking of FcγRIIIa. Binding curves were obtained by performing ELISA with serial dilutions of each
antibody (H3v-47, H3v-12, or control mAb VRC01 [to HIV]) onto HA-coated plates and assessing the ability of HA-bound mAbs to engage both Fc-binding
sites on the soluble FcγRIIIa dimer. b Primary NK cell activation. Antibody (H3v-47, H3v-12, or VRC01) at 0.1, 1, or 10 µg/mL each were added
independently on 96-well plates coated with purified A/Sydney/5/1997 H3 HA and incubated for 2 h. The plates were washed, and 5 × 105 purified NK
cells were added to each well. The cells were stained with anti-human CD107a allophycocyanin-H7 Ab, anti-human CD3 PerCP, anti-human CD56
allophycocyanin, and anti-IFNγ AF700. The data for 20,000–50,000 events were acquired using an LSRFortessa flow cytometer. The percentage of NK cell
activation was calculated as the percentage of NK cells that expressed CD107a and/or IFNγ. The dotted lines in both a and b indicate the limit of detection.
The results are representative of three independent experiments. Error bars indicate standard error of the mean (SEM)
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K173 in F005-126) (Fig. 7b–d). Moreover, H3v-47 targets the H3
HA globular head with a distinct angle of approach from those of
HC45 and F005-126 (Supplementary Figure 11). Although HC45
and BH151 also target the vestigial esterase subdomain, both are
A/Aichi/2/1968 strain-specific H3 antibodies with narrow
breadth of neutralization activity50,51. The footprint of F005-126
spans a cleft formed by two HA monomers in the head domain
(Fig. 7d) and neutralizes certain H3 viruses isolated during the
period from 1968 to 2004. On the other hand, H3v-47 spans the
RBS and vestigial esterase subdomain, recognizing an epitope
distinct from other H3-neutralizing antibodies.
Several antibodies were previously reported to bind to the
vestigial esterase subdomain: the H3-neutralizing mAbs HC45
and BH151, the H5-neutralizing mAb H5M9, and the influenza
type B neutralizing mAb CR807127,50–52. H3v-47 targets the HA
with a different approach angle from these antibodies (Fig. 8a).
HC45 neutralizes viral infectivity by blocking receptor binding, as
it has HAI activity51 and H5M9 prevents the low-pH induced
conformational changes of the HA required for membrane
fusion52. H3v-47 targets the vestigial esterase subdomain, but
binds closer to the RBS than H5M9, and their epitopes only partly
overlap (Fig. 8a, c). However, H3v-47 functions in a distinct
manner, because it does not prevent the low-pH-induced
conformational changes in the HA, nor does it have detectable
HAI activity. Instead, H3v-47 functions primarily by interfering
with progeny release similarly to the action of neuraminidase
inhibitors like zanamivir. Egress inhibition activity has been
recorded previously for an influenza type B antibody CR8071 that
binds to the HA head domain and is oriented perpendicular to
the long axis of the HA27 (Fig. 8a), recognizing a complex epitope
(Fig. 8b). The suggested inhibition mechanism for mAb CR8071
was by cross-linking newly formed virions to each other and to
HA on the cell membrane. It appears that H3v-47 functions in a
similar manner as CR8071 by tethering newly formed virions on
the cell surface despite binding to a different epitope, the vestigial
esterase subdomain23.
The H3v-47 antibody exhibits broad inhibitory activity for
human seasonal and swine H3 viruses isolated after ~1989, but
variability in the epitope does occur. E82 or K82 residues are
highly conserved (~100% conservation) across human and swine-
origin H3N2 strains isolated before or after 1989 (Supplementary
Figure 6b and Supplementary Table 5). The occurrence of the
natural antigenic drift mutation E82K is consistent with the cross-
neutralization activities of H3v-47 for human and swine H3
viruses isolated after ~1989. Moreover, the K82E variant disrupts
binding of H3v-47 Fab to the HA, indicating that the substitution
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Fig. 7 H3v-47 binds a unique epitope in the HA head domain. a Comparison of the binding site of H3v-47 (in magenta) wih structurally characterized H3-
binding antibodies binding to the HA head. The three protomers of the HA trimer are shown as surface in light, middle or dark gray, respectively. The HAs
from all these HA-antibody complexes are aligned. These antibodies include HC45 (PDB code 1QFU, green) and F005-126 (PDB code 3WHE, purple)
binding to the globular head below the receptor-binding site (RBS). For comparison, mAbs C05 (PDB code 4FP8), S139 (PDB code 4GMS), HC19 (PDB
code 2VIR), HC63 (PDB code 1KEN), and F045-092 (PDB code 4O58) all bind to the RBS. Because the epitopes of the RBS-binding antibodies overlap
extensively, their epitopes (in wheat) are depicted approximately around the RBS, to indicate their relative location compared to H3v-47. b–d Comparison
of the detailed epitopes recognized by H3v-47 (b), HC45 (c), and F005-126 (d)
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may play a major role in H3v-47 recognition and specificity, but
the antibody retains binding to such variants in the IgG form by
avidity effects. Because the natural antigenic variant E82K is
highly conserved, H3v-47 has the potential to neutralize most
circulating human and swine H3N2 viruses with this substitution.
Protective antibody responses to influenza vaccines typically
are evaluated using HAI assay that detect receptor-blocking
antibodies and by microneutralization assays that also detect
stem-binding antibodies and their fusion inhibiting properties.
These assays focus on detecting neutralizing antibodies that
function principally through the action of the antibody variable
domains. Fc-mediated ADCC activity has emerged as an
important additional mechanism for protection by influenza
stem-specific antibodies23,32,46,53. H3v-47 that binds to the ves-
tigial esterase subdomain on the HA head but does not block the
RBS was able to potently activate primary NK cells. The pro-
phylactic efficacy of H3v-47 seen in vivo may be due in part to its
ability to engage FcγRIIIa. A recent report showed the influenza B
virus-neutralizing antibody 46B8 targeting the vestigial esterase
domain can mediate ADCC, as well as block HA-mediated
membrane fusion54. Additionally, H5 neutralizing mAb 100F4
that binds to HA head but does not block receptor binding was
also shown to require Fc-mediated interactions to provide in vivo
protection55. Collectively, these results suggest that Fc–FcγR
interactions are important not only for HA-stem mAbs but also
for HA-head mAbs that target the vestigial esterase domain.
The human mAb H3v-47 showed broad neutralization of
human and swine H3N2 viruses by targeting a unique conserved
epitope that has not previously been characterized as immuno-
genic on H3 viruses. The structure of H3v-47 in complex with
H3v HA revealed that a region close to previously defined anti-
genic site E, containing the natural variant E82K, is a key site of
vulnerability. H3v-47 functions uniquely by inhibiting viral egress
and also by facilitating ADCC activity by engaging FcγRIIIa on
NK cells. This epitope may induce production of broadly neu-
tralizing antibodies against human and swine H3 viruses and
enable design of more broadly protective H3 vaccines.
Methods
Culture of influenza virus. The original seed stocks for all the viruses were
obtained from varying sources as recorded previously39. All of the working stocks
were obtained by virus inoculation of MDCK cell culture monolayers (American
Type Culture Collection, CCL-34) in plain Dulbecco Modified Eagle Medium
(Gibco DMEM, Invitrogen, 11965) with 2 µg/mL of TPCK-trypsin. High titered
stocks of Minn2010/H3v prepared in eggs were kindly provided by Richard Webby,
St. Jude Children’s Research Hospital, for use in mouse challenge studies.
Production of recombinant soluble HA proteins. The design and expression of
recombinant HA proteins for binding studies were described previously39.
Sequences encoding the HA genes were synthesized as soluble trimeric constructs
by replacing the transmembrane and cytoplasmic domain sequences with cDNAs
encoding the GCN4 trimerization domain and a His-tag at the C-terminus. Syn-
thesized genes were subcloned into the pcDNA3.1(+) mammalian expression
vector (Thermo Fisher Scientific) and expressed in FreeStyle 293-F cells (Thermo
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Fig. 8 Vestigial esterase subdomain-binding antibodies mediate neutralization by diverse mechanisms. a Comparison of H3v-47 (magenta) with
structurally characterized esterase subdomain-binding antibodies, including H5M9 binding to H5 HA (PDB code 4MHH, blue) and CR8071 (PDB code
4FQJ, orange) binding to influenza B HA. The HAs from all these complexes are aligned, and only the three protomers of A/Minnesota/11/2010 H3N2v HA
trimer are shown as surface in light, middle or dark gray, respectively. The HAs from all these HA-antibody complexes are aligned. The vestigial esterase
subdomain is highlighted in red. These antibodies target the HA vestigial esterase subdomain using different angles of approach. b-c The epitopes of
CR8071 (b) and H5M9 (c) are mapped onto the surfaces of the corresponding HAs
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Fisher Scientific). Recombinant soluble biotinylated HA proteins for the Kd mea-
surements and soluble HA proteins for crystallization and electron microscopy
(EM) studies were produced using a baculovirus expression system, as described
previously56.
Production of H3v-47 IgG. The H3v-47 human hybridoma cell line was generated
previously from a B cell in the blood of a subject immunized experimentally with
an H3N2v subunit vaccine and cloned as previously described39. The clones were
grown in 75 cm2 flasks to 70% confluency in hybridoma growth medium (Clo-
naCell-HY medium E from STEMCELL Technologies, 03805). The cells were
expanded equally to four 225 cm2 flasks for antibody expression in serum-free
medium (GIBCO Hybridoma-SFM, Invitrogen, 12045084). The supernatant was
collected after 3 weeks and purified by affinity chromatography using protein G
columns (GE Life Sciences, Protein G HP Columns). Purified H3v-47 IgG from
hybridoma cell expression was used for all EC50 and IC50 studies, egress assays,
TEM, and ADCC assays.
Half maximal effective concentration (EC50) and half maximal inhibitory
concentration (IC50) analysis. ELISAs were performed to obtain EC50 values for
binding using 384-well plates coated with the HA of interest at a 2 μg/mL con-
centration and incubated overnight at 4 °C. The plates were blocked with 5% non-
fat dry milk, 2% goat serum, and 0.1% Tween-20 in PBS for 1 h. Three-fold
dilutions of the mAb, starting from 10 μg/mL, were added to the wells, incubated
for 1 h, followed by a 1 h incubation of a 1:4000 dilution of anti-human IgG
alkaline phosphatase conjugate (Meridian Life Science, W99008A). The plates were
washed three times between each step with PBS containing 0.1% Tween-20.
Phosphatase substrate solution (1 mg/mL p-nitrophenol phosphate in 1M Tris
aminomethane) was added to the plates, incubated for 1 h, and the optical density
values were measured at 405 nm wavelength on a BioTek plate reader. Each
dilution was performed in triplicate, and the EC50 values were calculated in Prism
software (GraphPad) using non-linear regression analysis.
For microneutralization, 50 μL of two-fold serial dilutions of each antibody,
starting at a 20 μg/mL concentration, was incubated with 50 μL of 100 TCID50 of
the virus in viral growth medium (VGM) for 1 h at RT. VGM consisted of plain
DMEM with 2 μg/mL of TPCK-trypsin and 50 μg/mL gentamicin. The MDCK cell
monolayer cultures were washed twice with 100 μL PBS containing 0.1% Tween-20,
and the virus-antibody mixture then was added to cells and incubated for 32 h at
37 °C. The cells were washed again and fixed with 100 μL of 80% methanol/20%
PBS. The presence of influenza nucleoprotein in the fixed cells was determined by
ELISA using a 1:8000 dilution of mouse anti-NP antibody (BEI Resources, NR
4282) as the primary antibody and a 1:4000 dilution of goat anti-mouse alkaline
phosphate conjugate as the secondary antibody (Thermo Fisher Scientific, 31320).
Each dilution was tested in duplicate and the half-maximal inhibitory
concentration (IC50) was determined by non-linear regression analysis of log10
[inhibitor] vs. response function, using Prism software (GraphPad). An IC50 value
of 2 μg/mL was used as the threshold to determine the presence of functional
neutralization. The experiments for determining EC50 (n= 4) and IC50 (n= 3)
were conducted twice independently. Plaque reduction assay was used to determine
IC50 values for H3v-47 against swine H3N2 strains. MDCK cells were seeded onto
the 12-well tissue culture plates the day before inoculation. On the next day, 50 pfu
of each H3N2 virus in 100 μL was first incubated with two-fold serially diluted
antibodies for 1 h at 37 °C. The mixture was then added onto MDCK cells after
removing their culture medium and incubated for 1 h at 37 °C. Plaque formation
was assessed after a 2–3 day incubation at 37 °C. The inhibition mediated by
H3v-47 antibody against each H3N2 virus was calculated as the percentage of the
plaque reduction, and IC50 values were determined as the concentration at which
50% of plaque reduction was observed.
Expression of recombinant H3v-47 Fab. The heavy and light chain variable
regions of H3v-47 were cloned into the vector phCMV containing the CH1 region
of an IgG1 appended to myc- and His-tags, respectively. The Fab fragment was
expressed by transient co-transfection of the expression vector containing heavy
chain and light chain into FreeStyle 293-F cells. Recombinant Fab was purified
from culture supernatant using a nickel column followed by size exclusion chro-
matography using a Superdex 75 column (GE Healthcare). Purified Fab was
measured by optical absorbance at 280 nm, and purity and integrity were analyzed
by reducing and nonreducing SDS-PAGE. The purified H3v-47 Fab was con-
centrated to ~10 mg/mL for crystallization and Kd determination.
Kd determination. Kd values were determined by bio-layer interferometry using an
Octet RED instrument (ForteBio, Inc.), as described previously36. Biotinylated HA
proteins were loaded onto streptavidin-coated biosensors in 1× kinetics buffer (1×
PBS, pH 7.4, 0.01% bovine serum albumin [BSA], and 0.002% Tween 20) for 600 s.
For measurement of kon, association of H3v-47 IgG/Fab was measured for 180–600
s by exposing the sensors to four to six concentrations of Fab in
1× kinetics buffer. For measurement of koff, dissociation of H3v-47 IgG/Fab was
measured for 180–600 s in 1× kinetics buffer. Experiments were performed at
30 °C. The ratio of koff to kon was used to calculate the Kd. All binding traces and
curves used for fitting are reported in Supplementary Figure 1.
Competition-binding groups. Biolayer interferometry using an Octet Red
instrument (ForteBio) was used to perform competition-binding assays. The HA
was loaded onto ForteBio Ni-NTA tips at a concentration of 20 μg/mL, and binding
to two successively applied mAbs at 50 μg/mL was tested. All of the dilutions were
made in 1 × kinetic buffer (ForteBio, 18-5032). The individual binding signal for
each mAb was obtained after 300 s of a single association step of the mAb on to
HA. For competition analysis, if binding of the first antibody blocked the binding
of the second antibody by reducing its actual binding signal by more than 70%, it
was defined as a competitor. If binding of the first antibody did not block the
binding of the second antibody by reducing its actual binding signal by less than
30%, it was defined as a noncompetitor. A signal reduction between 30 and 70%
was defined as partial blocking.
Antibody treatment of mice. All protocols were reviewed and approved by the
Vanderbilt University Institutional Animal Care and Use Committee. Briefly, 7-
week old female DBA/2J mice (purchased from Jackson Labs) were sorted ran-
domly into groups of 15 animals. Groups included prophylaxis (with antibody
delivered one day before virus inoculation, designated day −1) or treatment (with
antibody delivered 1 day after virus inoculation, designated day +1) using mock
treatment with phosphate buffered saline, mAb H3v-47 or a positve control
antibody (CR-8020). Treatment doses for mAb H3v-47 were 10 or 1 mg/kg and for
control antibody was 10 mg/kg. All treatments were administered by the intra-
peritoneal route.
Virus challenge and determination of efficacy of mAbs against infection and
disease. All mice in the mAb prophylaxis or treatment studies were challenged
with ∼ 6 × 104 FFU of A/Minnesota/11/2010 ×−203 via intranasal administration
in 50 µL of sterile PBS. Animals were observed daily for signs of illness and for
body weight changes. On day +4 after virus inoculation, five (5) mice per group
were collected and lungs were collected for lung virus load analysis. Lungs were
homogenized (Biospec Products, USA) in 1.0 mL of sterile PBS, and serial dilutions
of tissue homogenate were evaluated for viral load by a focus forming assay on
MDCK monolayers.
Protease susceptibility assay. Experiments to test for trypsin susceptibility of the
HA were performed as previously described36. For A/Minnesota/11/2010 (H3N2)
HA, each reaction mixture contained 2.5 µg of the HA or 2.5 µg of the HA and a
two-fold molar excess of H3v-47 Fab (two Fabs per HA protomer). Reaction
mixtures were incubated at 37 °C for 1 h at pH 5.0 and at 8.0. After incubation, the
reaction mixture was neutralized to pH 8.4. Trypsin then was added to all samples
except controls at a final ratio of 1:20 (wt/wt) of trypsin to HA, and reaction
mixtures were incubated overnight at 22 °C. Samples then were analyzed by
non-reducing SDS-PAGE.
Egress inhibition assay. MDCK cells were seeded in plain Dulbecco Modified
Eagle Medium (Gibco DMEM, Invitrogen, 11965) containing 10% FBS on six-well
plates overnight. The cells were washed three times with PBS and 200 µL of pre-
viously optimized virus titer required to achieve 90–100% infection was added to
the cells and incubated for 1 h at 37 °C degrees with periodic shaking. One hour
after inoculation, the cells were washed once and replenished with 2 mL Opti-
MEM I with GlutaMAX medium (Gibco, Life Technologies, 51985) per well and
incubated for two more hours at 37 °C degrees. After a total of 3 h after inoculation,
the cells were washed again and replenished with medium containing three-fold
serial dilutions of H3v-47 antibody, CR8020 antibody or zanamivir (Relenza,
NDC0713068101), starting at the highest concentration of 10 µg/mL. Trypsin was
not added to the cells, in order to restrict the infection to a single cycle. The plates
were incubated for 12 h at 37 °C degrees and the supernatants were collected for
performing the HA assay. For HA assay, we used turkey red blood cells (Rockland
Immunochemicals, R313) that were washed and diluted to 0.5% in 2.5% sodium
citrate. A volume of 50 µL of the supernatants that were serially diluted two-fold in
medium were incubated with 50 µL of the 0.5% turkey red blood cells in v-bottom
plates for 1 h at 4 °C. The HA titers in the supernatants were calculated based on
the lowest supernatant dilution at which hemagglutination was observed. The HA
titers were performed in triplicate, and results shown are an average of three wells.
Transmission electron microscopy. MDCK cells were inoculated with A/
Minnesota/11/2010 H3N2v virus and subsequently incubated with H3v-47 IgG
(5 µg/mL), CR8020 IgG (10 µg/mL), Zanamivir, or plain Opti-MEM I medium at 3
h postinoculation using the same conditions as the egress assay. Trypsin was not
added to cells to preserve surface filaments, in order to assess egress inhibition. For
gold labeling, the samples were treated identically except for the addition of goat-
anti-human IgG conjugated to 10 nm gold particles (EMS, 25208) at 13 h post-
inoculation. At 14 h after virus inoculation, samples were washed with 0.1 M
cacodylate buffer and fixed in 2.5% gluteraldehyde in 0.1 M cacodylate buffer, pH
7.4 at room temperature (RT) for 1 h then transferred to 4 °C, overnight. The
samples were washed in 0.1 M cacodylate buffer, then incubated 1 h in 1% osmium
tetraoxide at RT, then washed with 0.1 M cacodylate buffer. Subsequently, the
samples were dehydrated through a graded ethanol series and then three exchanges
of 100% ethanol. Next, the samples were incubated for 5 min in 100% ethanol and
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propylene oxide (PO) followed by two exchanges of pure PO. Samples then were
infiltrated with 25% Epon 812 resin and 75% PO for 30 min at RT. Next, they were
infiltrated with Epon 812 resin and PO [1:1] for 1 h at RT, and then overnight at
RT. The next day, the samples underwent a 3:1 (resin: PO) exchange for 3–4 h,
then were incubated with pure epoxy resin overnight. Samples then were incubated
in two more changes of pure epoxy resin and allowed to polymerize at 60 °C for 48
h. For imaging, 70–80 nm ultra-thin sections were cut and collected on 300-mesh
copper grids and post-stained with 2% uranyl acetate, and then with Reynold’s lead
citrate. Samples subsequently were imaged on a Philips/FEI Tecnai T12 electron
microscope at varying magnifications. Specimens were processed for TEM and
imaged in the Vanderbilt Cell Imaging Shared Resource – Research Electron
Microscopy facility.
Dimeric recombinant soluble FcγRIIIa (CD16a) binding ELISA. A dimeric
recombinant soluble FcγRIIIa (rsFcγRIIIa) ELISA was used to model the need for
ADCC-inducing Abs to cross link FcγRIIIa48. A 96-well ELISA plate was coated
with 50 ng of purified influenza HA protein from H3N2 A/Sydney/5/1997 (Sino
Biological Inc., 40149-V08B) protein overnight at 4 °C in PBS. The plate was
washed twice with PBST and blocked with 140 µL of PBS 1 mM EDTA, 1% BSA
(PBSE/BSA) for 1 h at 37 °C. The plate then was washed twice with PBST and 50 µL
of H3v-47 diluted in PBSE/BSA was added into duplicate wells, with concentra-
tions ranging from 40 μg/mL to 2.4 ng/mL. Negative control wells with HA protein
and PBS alone also were included (“no antibody control”). Following addition of
H3v-47 or PBS, the plate was incubated at 37 °C for 1 h. The ELISA plate was
washed five times with PBST and 50 µL of 0.1 µg/mL rsFcγRIIIa (V176) dimer was
added to the wells, then the plate was incubated for 1 h at 37 °C. Pierce High
Sensitivity Streptavidin-HRP (Thermo Fisher Scientific, 21130) was diluted
1:10,000 in PBSE/BSA, added to all wells, and the plate was incubated at 37 °C for
1 h. The plate was washed eight times with PBST and blotted dry. A volume of 50
µL of TMB substrate was added to each well and the plate was developed for 4–8
min in the dark. The reaction was stopped with 1M HCl and the plate read at an
absorbance of 450 nm.
NK cell activation assay. A total of 96-well ELISA plates were coated with 600 ng
of purified influenza H3N2 A/Sydney/5/1997 HA protein (Sino Biological Inc.,
40149-V08B) overnight at 4 °C in PBS. The wells were washed five times with PBS
and incubated with 10 μg/mL, 1 μg/mL or 0.1 μg/mL of H3v-47 diluted in PBS for 2
h at 37 °C. Negative control wells with HA protein and PBS alone also were included
(“no antibody control”). Plates were washed seven times with PBS, and 5 × 105
purified NK cells were added to each well. Healthy donor PBMCs were isolated with
Ficoll-Paque PLUS (GE Healthcare Life Sciences, 171440). NK cells were purified
from freshly isolated PBMCs using the EasySep human NK cell enrichment kit
(STEMCELL Technologies, 19055) and resuspended in RF10 medium (RPMI
1640 supplemented with 10% FCS, penicillin, streptomycin, and l-glutamine).
Mouse anti-human CD107a allophycocyanin-H7 antibody (clone H4A3, BD Bios-
ciences, 561343; used at a 1:160 dilution), 5 μg/mL brefeldin A (Sigma-Aldrich,
B6542), and 5 μg/mL monensin (BD GolgiStop; BD Biosciences, 554724) were
added to the cells and incubated for 5 h at 37 °C in 5% CO2. Purified NK cells then
were incubated with 1 mM EDTA to minimize cell adherence to the plates, anti-
human CD3 PerCP (clone SP34-2, BD Biosciences, 552851, used at a 1:40 dilution),
and anti-human CD56 allophycocyanin (clone B159, BD Biosciences, 555518; used
at a 1:20 dilution) for 30 min at room temperature in the dark. Cells were fixed with
1% formaldehyde for 10 min and permeabilized with FACS permeabilizing solution
two (BD Biosciences, 347692) for 10min. PBMCs then were incubated at room
temperature for 1 h with anti-human IFNγ AF700 (clone B27; BD Biosciences,
561024; used at a 1:400 dilution) in the dark. Finally, cells were again fixed with 1%
formaldehyde and data sets for 20,000–50,000 events were acquired using an
LSRFortessa flow cytometer (BD Biosciences). The experiment was performed twice
independently, with duplicate wells tested in each experiment.
Crystallization and X-ray structure determination. Apo H3v-47 Fab and apo
Minn2010/H3v HA crystals were grown using our automated Rigaku Crystal-
mation robotic system at The Scripps Research Institute by sitting drop vapor
diffusion. Crystals of H3v-47 Fab (10 mg/mL) grew at 20 °C using 20% (w/v)
polyethylene glycol (PEG) 6000, 0.1 M sodium citrate (pH 5.0) as precipitant.
Crystals were cryo-protected in mother liquor supplemented with 15% (w/v) gly-
cerol, flash cooled, and stored in liquid nitrogen until data collection. Crystals of
Minn2010/H3v HA (10 mg/ml) grew at 20 °C with 0.2 M calcium acetate, 18%
(w/v) polyethylene glycol PEG 8000, 0.1 M sodium cacodylate (pH 6.5) as pre-
cipitant. Complexes of the HA with human receptor analog LSTc were obtained by
soaking HA crystals in precipitant solution that contained glycan ligands in a final
concentration of 5 mM. Crystals were cryo-protected in mother liquor supple-
mented with 15% (w/v) glycerol, flash cooled, and stored in liquid nitrogen until
data collection. X-ray diffraction data for the H3v-47 Fab apo, Minn2010/H3v HA
apo, and HA-LSTc complex were collected to 2.57, 3.15, and 2.90 Å resolutions at
beamline 23ID-D at the Advanced Photon Source (APS), respectively. The dif-
fraction data from H3v-47 Fab and Minn2010/H3v HA were processed using
HKL2000 in spacegroups P31 and I213, respectively57. The crystal structure of
H3v-47 Fab was determined by molecular replacement with Phaser58 using the
variable and constant domains of an Fab in the PDB (4Q9Q) as a search model;
two Fabs were found in the asymmetric unit. The model was iteratively rebuilt
using Coot59 and refined in Phenix60. Refinement parameters included rigid body
refinement (for each Ig domain), simulated annealing, and restrained refinement
including TLS refinement (for each Ig domain). The initial Minn2010/H3v HA apo
structure was solved by molecular replacement method using Phaser58 with an H3
HA structure (PDB code 2YP2) as a search model. The H3v HA apo structure was
used as the starting model for structure determination of the H3v HA-LSTc
complex structure. Structure refinement was carried out in Phenix60 and model
building with COOT59.
The H3v-47-Minn2010/H3v HA complex was prepared by adding recombinant
H3v-47 Fab to HA in a 1.2:1 molar ratio and the saturated complex was purified by
gel filtration. Crystals of the complex (~8mg/mL) were grown by sitting drop vapor
diffusion at 20 °C with 10% (v/v) 2-methyl-2,4-pentanediol (MPD), 0.1M MES (pH
5.0) as precipitant. Crystals were cryo-protected in mother liquor supplemented
with 10% MPD, flash cooled, and stored in liquid nitrogen until data collection. X-
ray diffraction data for the H3v-47-Minn2010/H3v HA complex were collected to
3.57 Å resolution at APS beamline 23ID-D and processed in spacegroup P213 using
HKL200057. The structure was determined by molecular replacement with Phaser58
using H3v-47 Fab apo and Minn2010/H3v HA-LSTc complex (instead of apo form)
as the search model. The model was iteratively rebuilt using Coot59 and refined in
Phenix60. Refinement parameters included rigid body refinement (for the HA and
for the variable and constant domains of each Fab), restrained refinement including
TLS refinement (for the HA and for the variable and constant domains of Fab),
using the high-resolution HA and Fab as reference models. Final refinement
statistics are summarized in Supplementary Table 2.
Structural analyses. Hydrogen bonds and van der Waals contacts were calculated
using HBPLUS61 and CONTACSYM62, respectively. The surface area buried upon
Fab binding was calculated using MS63. MacPyMOL (DeLano Scientific) was used
to render figures. Kabat numbering was applied to the coordinate files using the
AbNum server64. The final coordinates were validated using the JCSG quality
control server (v2.8), which includes MolProbity65.
EM structures of H3v-47-HA complexes. Complexes were prepared by mixing
the HA with saturating amounts of H3v-47 Fab and FI6v Fab at room temperature
for 2 h. The complex was purified by size exclusion chromatography using a
Superdex 200 10/300 GL column (GE Healthcare) to remove excess Fab. The
complex was diluted to 2 ug/ml, applied to freshly glow discharged 400 mesh
carbon coated copper grids, and negatively stained with 2% uranyl formate. The
complexes were imaged at 52K times magnification on an FEI T12 at 120 kV TEM
resulting in a pixel size of 2.05 A/pixel (calibrated using catalase crystal diffraction)
with a dose of 24.7 e/Å2. All data were collected using Leginon Multi-Scale Imaging
(MSI-raster 3.1) software66. The T12 TEM was equipped with a Teitz F416 4k × 4k
CMOS. Images were collected while tilting the stage from 0 to 50 degrees in
5-degree increments to increase sampling of different angular orientations of the
particles. DoGpicker67 was used to automatically select particles from 599 raw
micrographs that were then binned by two resulting in 4.10 Å /pixel size and placed
into 80 × 80 pixel boxes. Particles were aligned with Iterative MRA-MSA and
ISAC1 resulting in a final stack of 23,175 raw particles. Class averages from ISAC
were used to create a common lines initial model in EMAN268. Model refinement
was conducted in EMAN169 resulting in a 25.8 Å resolution reconstruction based
on a 0.5 FSC cutoff value.
Sequence analysis of the antibody epitopes. The full-length and non-redundant
influenza A HA sequences were downloaded from the Influenza Virus Resource at
the National Center for Biotechnology Information (NCBI) database70. At the time
of download (December 31, 2015), the dataset includes 4859 human H3 HA
sequences. The sequences were aligned using MUSCLE71 with default parameters.
Data availability. Atomic coordinates and structure factors for the crystal struc-
tures of H3v-47 Fab, A/Minnesota/11/2010 (H3N2) HA in apo form, the HA in
complex with LSTc, and the HA in complex with H3v-47 Fab have been deposited
in the Protein Data Bank with the accession codes 5XRQ, 5XRT, 5XRS, and 5W42,
respectively. The authors declare that all other data supporting the findings of this
study are available within the article and its Supplementary Information files, or are
available from the authors upon request.
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